Analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Caribou Biosciences (CRBU – Research Report), reducing the price target to $3.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Robert Burns has given his Buy rating due to a combination of factors that reflect Caribou Biosciences’ strategic focus and financial positioning. The company has recently decided to concentrate its resources on its leading oncology programs, which involves halting certain trials and reducing its workforce. This strategic shift is expected to extend Caribou’s operational runway, providing a more stable financial outlook despite the lowered price target.
Furthermore, Burns points to upcoming clinical data presentations as potential catalysts for the stock. These include results from the Phase 1 CaMMouflage trial and additional data from the ANTLER trial, both expected in the second half of 2025. Despite adjustments in the company’s valuation model, such as a higher discount rate and reduced growth projections, Burns maintains a Buy rating, believing that Caribou remains undervalued and in a strong position to navigate market volatility.
In another report released on April 24, Leerink Partners also maintained a Buy rating on the stock with a $3.00 price target.